Heart Health Heart Disease Diagnosis Thallium and Technetium Heart Scans Overview By Richard N. Fogoros, MD Richard N. Fogoros, MD Facebook LinkedIn Richard N. Fogoros, MD, is a retired professor of medicine and board-certified internal medicine physician and cardiologist. Learn about our editorial process Updated on June 13, 2022 Medically reviewed by Yasmine S. Ali, MD, MSCI Medically reviewed by Yasmine S. Ali, MD, MSCI Facebook LinkedIn Twitter Yasmine S. Ali, MD, MSCI, is a board-certified preventive cardiologist and lipidologist. Dr. Ali is also an award-winning writer. Learn about our Medical Expert Board Print Several non-invasive tests are useful in the evaluation of coronary artery disease (CAD). Among the most useful are heart scans performed with either thallium or technetium. Stockbyte / Getty Images Thallium-201 and technetium-99m sestamibi (Cardiolite) are two radioactive substances used in tests, called “nuclear perfusion studies,” that look for blockages in the coronary arteries. By injecting thallium or technetium into the bloodstream, usually during a cardiac stress test, an image of the heart can be made that shows how well blood is flowing to the various parts of the heart muscle. If a coronary artery is partially or completely blocked because of CAD, the muscle being supplied by the diseased artery will show up on the image as a dark spot—an area of reduced or absent blood flow. What Are Thallium and Sestamibi? Thallium and technetium are radioactive substances that have been used for many years in cardiac imaging studies. When injected into the bloodstream, these substances attach to certain kinds of cells, including heart muscle cells. A special imaging camera that detects radioactivity can then be used to make an image of the heart muscle that has gathered the thallium or technetium. However, thallium and technetium attach only to the portions of heart muscle that have good blood flow. If one of the coronary arteries is blocked or partially blocked, relatively little radioactivity reaches the muscle supplied by that blocked artery. How Nuclear Perfusion Studies Are Performed During a stress test, either thallium or technetium is injected into a vein at the point of maximum exercise. The radioactive substance then distributes itself throughout the heart muscle, in proportion to the blood flow received by that muscle. Cardiac muscle receiving normal blood flow accumulates a larger amount of thallium/technetium than cardiac muscle that is obstructed by an atherosclerotic plaque. When patients need stress testing but are unable to exercise, adenosine or a newer drug, regadenoson, is injected into a vein to simulate exercise. Adenosine causes blood flow to redistribute in the heart muscle in a manner similar to exercise—areas with a partial blockage receive relatively less blood flow for a few minutes after an adenosine injection. An image of the heart will then be made by a camera that can "see" the radioactivity emitted by thallium, technetium, or another drug. From these pictures, any portions of the heart that are not receiving normal blood flow (because of blockage in the coronary arteries) can be identified as “dark spots.” Benefits Using thallium or technetium perfusion imaging greatly increases the accuracy of a stress test in diagnosing obstructive CAD. A normal thallium/technetium test is an excellent indication that there are no significant blockages in the coronary arteries. On the other hand, patients with abnormal perfusion scans are highly likely to have significant blockages. Nuclear perfusion studies are used in three general circumstances. First, they are useful in patients who are suspected to have stable angina due to fixed blockages in the coronary arteries. Second, these studies are used in patients who have been treated medically (that is, non-invasively) for unstable angina or non-ST-segment myocardial infarction (NSTEMI), and who have appeared to stabilize. If their thallium/technetium tests show no significant residual blockages, it is relatively safe to continue with medical therapy alone. Otherwise, they should be considered for angioplasty and stenting, or for bypass surgery. Third, these studies are used to assess the viability of the heart muscle beyond a severe blockage in a coronary artery. If the heart muscle “lights up” to any extent with thallium/technetium, then it is still partially viable—and stenting or bypassing the artery can be expected to improve the function of the heart. Otherwise, a revascularization procedure would not be expected to provide many benefits. Risks These noninvasive studies are quite safe. Their only drawback is that a small amount of radiation is used. The level of radiation the patient receives is thought to produce a very small risk of harm, if any, and for appropriately selected patients the potential for benefit far outweighs this small risk. Sources Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact ofrevascularization on prognosis in patients with coronary artery disease andleft ventricular dysfunction: A meta-analysis. J Am Coll Cardiol. 2002 Apr3;39(7):1151-8. doi: 10.1016/s0735-1097(02)01726-6 Anderson JL et al. ACC/AHA 2007 guidelines forthe management of patients with unstable angina/non-ST-Elevation myocardialinfarction: A report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines (Writing Committee to Revise the2002 Guidelines for the Management of Patients With UnstableAngina/Non-ST-Elevation Myocardial Infarction) developed in collaboration withthe American College of Emergency Physicians, the Society for CardiovascularAngiography and Interventions, and the Society of Thoracic Surgeons endorsed bythe American Association of Cardiovascular and Pulmonary Rehabilitation and theSociety for Academic Emergency Medicine. J Am Coll Cardiol. 2007 Aug14;50(7):e1-e157. doi:10.1016/j.jacc.2007.02.013 By Richard N. Fogoros, MD Richard N. Fogoros, MD, is a retired professor of medicine and board-certified in internal medicine, clinical cardiology, and clinical electrophysiology. See Our Editorial Process Meet Our Medical Expert Board Share Feedback Was this page helpful? Thanks for your feedback! What is your feedback? Other Helpful Report an Error Submit